Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
IC-MPGN: full-pipeline trial registry
2 of 4 indexed IC-MPGN trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
IC-MPGN: 4 US clinical trials tracked, 2 recruiting.
IC-MPGN is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Apellis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition ic-mpgn
OPEN 2 | RECR 50% | LATE 2 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
IC-MPGN lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for IC-MPGN on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
IC-MPGN is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Novartis Pharmaceuticals
NCT05755386
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ADARx Pharmaceuticals
NCT06989359
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Apellis Pharmaceuticals
NCT05809531
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Apellis Pharmaceuticals
NCT04572854
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on IC-MPGN records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on IC-MPGN trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this IC-MPGN page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 IC-MPGN trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Apellis Pharmaceuticals sponsors the most IC-MPGN trials on record, review their full trial history before evaluating a specific study. See Apellis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IC-MPGN condition card totals 4 registered trials; most-linked intervention Pegcetacoplan; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.